HYPERTENSION AND THE GUT MICROBIOME: USING GUT MICROBES TO REDUCE BLOOD PRESSURE
Professor Francine Marques
Professor of Genetics and Genomics
Monash University, Victoria, Australia
RESEARCHER PROFILE (Filmed in Clayton, Victoria | December 2024)
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
As a researcher Professor Marques has secured over $10 million in competitive funding as a principal investigator. She has won 31 awards, including the 2019 American Heart Association Hypertension Council Goldblatt Award, the 2020 High Blood Pressure Research Council of Australia and 2021 International Society of Hypertension Mid-Career Awards, the 2021 Australian Academy of Science Gottschalk Medal, and the 2024 Australian Society of Medical Research Peter Doherty Leading Light Award, and was a finalist for 12 awards, including the Eureka Prize Emerging Leader in Science.
Her research team aims to build exceptional scientists that help improve cardiovascular health, using translational approaches to lower blood pressure via the gut microbiome. Professor Marques is also passionate about equity, diversity and inclusion (EDI) and helping communities change the current culture of research.
She has led research identifying intrinsic equity issues in the cardiovascular research community in Australia (https://pubmed.ncbi.nlm.nih.gov/32839116/), followed by research to find solutions for these issues (https://pubmed.ncbi.nlm.nih.gov/35577952/), resulting in the 2021 Women’s Agenda Emerging Leader in STEM award.
Outside work, Francine enjoys baking, travelling, spending time with family, friends and her dogs, and reading books.
https://orcid.org/0000-0003-4920-9991
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
